Vaccine Fill Finish Delpharm has demonstrable vaccine fill-finish experience including collaborations with Pfizer and BioNTech for COVID vaccines, and recent investments in a sterile line for prefilled syringes in Tours, signaling readiness to scale biologics and vaccine manufacturing.

North America Growth Active expansion in North America with a major facility upgrade in Canada and ongoing work manufacturing injectable products for Sandoz Canada, supported by recent financing, signaling capacity to serve North American supply chains and complex injectables.

Diverse Capabilities Broad capability across dosage forms and end to end development supports a one stop CDMO model from early phase development to commercial scale.

Strategic Partnerships Proven track record with major pharmaceutical partners including BioNTech and Pfizer demonstrates ability to secure large vaccine and injectable programs and to collaborate on complex supply chains.

Global Footprint Extensive geographic footprint across multiple European countries and North America, backed by a sizeable workforce and a broad production base, positions Delpharm to absorb diverse client pipelines and to scale with growing demand.